IADR Abstract Archives
FRISBEE: Botulinum Toxin Type A for Sleep Bruxism in Adults
Objectives: This research aims to determine the effectiveness of Botulinum toxin type A (BoNTA) to manage sleep bruxism in adults.
Methods: A search of relevant studies including multiple databases such as MEDLINE, EMBASE, Cochrane was performed through Epistemonikos. Data from identified systematic reviews was extracted using a standardized sheet form and outcomes from primary studies was analyzed. The primary outcomes included bruxism events during sleep. As secondary outcomes we considered the following: Sleep time, sleep quality, tooth wear index, muscle pain and adverse effects. Then, a structured summary named FRISBEE (Friendly Summaries of Body of Evidence using Epistemonikos) was generated following a protocol that included key messages, a matrix of evidence in Epistemonikos (summary of the analyzed evidence), a summary of the results using the GRADE approach and a decision-making section.
Results: The search strategy retrieved fifteen relevant systematic reviews in Epistemonikos. Two randomized clinical trials involving 35 patients were selected to extract the relevant information. Both studies used placebo (saline solution) as control. One study used bilateral injection of BoNTA in the masseter and temporal muscles, and one study implemented bilateral BoNTA injection in the masseter muscles. The dose range was between 20U and 100U of BoNTA and the follow up evaluation from 1 to 3 months. Both trials measured the bruxism events using electromyography, without significant difference between groups.
Conclusions: There is no enough evidence to support the use of BoNTA to manage sleep bruxism in adults.
Methods: A search of relevant studies including multiple databases such as MEDLINE, EMBASE, Cochrane was performed through Epistemonikos. Data from identified systematic reviews was extracted using a standardized sheet form and outcomes from primary studies was analyzed. The primary outcomes included bruxism events during sleep. As secondary outcomes we considered the following: Sleep time, sleep quality, tooth wear index, muscle pain and adverse effects. Then, a structured summary named FRISBEE (Friendly Summaries of Body of Evidence using Epistemonikos) was generated following a protocol that included key messages, a matrix of evidence in Epistemonikos (summary of the analyzed evidence), a summary of the results using the GRADE approach and a decision-making section.
Results: The search strategy retrieved fifteen relevant systematic reviews in Epistemonikos. Two randomized clinical trials involving 35 patients were selected to extract the relevant information. Both studies used placebo (saline solution) as control. One study used bilateral injection of BoNTA in the masseter and temporal muscles, and one study implemented bilateral BoNTA injection in the masseter muscles. The dose range was between 20U and 100U of BoNTA and the follow up evaluation from 1 to 3 months. Both trials measured the bruxism events using electromyography, without significant difference between groups.
Conclusions: There is no enough evidence to support the use of BoNTA to manage sleep bruxism in adults.